Topic
Urinary retention
About: Urinary retention is a research topic. Over the lifetime, 5807 publications have been published within this topic receiving 110151 citations. The topic is also known as: increased post-void residual urine volume.
Papers published on a yearly basis
1 / 2
Papers
University of Texas Southwestern Medical Center1, George Washington University2, Washington University in St. Louis3, New York University4, National Institutes of Health5, Northwestern University6, Emory University7, University of Colorado Denver8, Beaumont Hospital9, San Antonio Military Medical Center10, Yale University11, University of Maryland, Baltimore12, NewYork–Presbyterian Hospital13, University of Iowa14, Mayo Clinic15, Henry Ford Health System16, Vanderbilt University17, University of California, San Diego18, Walter Reed Army Institute of Research19, Baylor College of Medicine20
TL;DR: Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.
Abstract: background Benign prostatic hyperplasia is commonly treated with alpha-adrenergic–receptor antagonists (alpha-blockers) or 5 a -reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown. methods We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia. results The risk of overall clinical progression — defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection — was significantly reduced by doxazosin (39 percent risk reduction, P<0.001) and finasteride (34 percent risk reduction, P=0.002), as compared with placebo. The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone. The risks of acute urinary retention and the need for invasive therapy were significantly reduced by combination therapy (P<0.001) and finasteride (P<0.001) but not by doxazosin. Doxazosin (P<0.001), finasteride (P =0.001), and combination therapy (P<0.001) each resulted in significant improvement in symptom scores, with combination therapy being superior to both doxazosin (P=0.006) and finasteride (P<0.001) alone. conclusions Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone. Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy.
2,033 citations
TL;DR: TURP still represents the gold standard for managing benign prostatic hyperplasia with decreasing complication rates and technological improvements such as microprocessor-controlled units, better armamentarium such as video TUR, and training helped to reduce perioperative complications.
1,297 citations
TL;DR: The 2013 version of the European Association of Urology guidelines on the treatment and follow-up of male lower urinary tract symptoms (LUTS) provides practical guidance for the management of men experiencing LUTS.
1,259 citations
TL;DR: To revise the 2003 version of the American Urological Association's (AUA) Guideline on the management of benign prostatic hyperplasia, new pharmacotherapies and technologies have emerged which have impacted treatment algorithms.
1,183 citations
Washington University in St. Louis1, Emory University2, Thomas Jefferson University3, Medical University of Vienna4, Vita-Salute San Raffaele University5, University of Texas Health Science Center at Houston6, Universidade Federal de Ciências da Saúde de Porto Alegre7, Mayo Clinic8, GlaxoSmithKline9
TL;DR: Over the course of the 4-year study period, dutasteride reduced the risk of incident prostate cancer detected on biopsy and improved the outcomes related to benign prostatic hyperplasia.
Abstract: Background We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Methods In this 4-year, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study, we compared dutasteride, at a dose of 0.5 mg daily, with placebo. Men were eligible for inclusion in the study if they were 50 to 75 years of age, had a prostate-specific antigen (PSA) level of 2.5 to 10.0 ng per milliliter, and had had one negative prostate biopsy (6 to 12 cores) within 6 months before enrollment. Subjects underwent a 10-core transrectal ultrasound-guided biopsy at 2 and 4 years. Results Among 6729 men who underwent a biopsy or prostate surgery, cancer was detected in 659 of the 3305 men in the dutasteride group, as compared with 858 of the 3424 men in the placebo group, representing a relative risk reduction with dutasteride of 22.8% (95% confidence interval, 15.2 to 29.8) over the 4-year study period (P<0.001). Overall, in years 1 through 4, among the 6706 men who underwent a needle biopsy, there were 220 tumors with a Gleason score of 7 to 10 among 3299 men in the dutasteride group and 233 among 3407 men in the placebo group (P = 0.81). During years 3 and 4, there were 12 tumors with a Gleason score of 8 to 10 in the dutasteride group, as compared with only 1 in the placebo group (P = 0.003). Dutasteride therapy, as compared with placebo, resulted in a reduction in the rate of acute urinary retention (1.6% vs. 6.7%, a 77.3% relative reduction). The incidence of adverse events was similar to that in studies of dutasteride therapy for benign prostatic hyperplasia, except that in our study, as compared with previous studies, the relative incidence of the composite category of cardiac failure was higher in the dutasteride group than in the placebo group (0.7% [30 men] vs. 0.4% [16 men], P = 0.03). Conclusions Over the course of the 4-year study period, dutasteride reduced the risk of incident prostate cancer detected on biopsy and improved the outcomes related to benign prostatic hyperplasia. (ClinicalTrials.gov number, NCT00056407.)
1,169 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2025 | 104 |
| 2024 | 178 |
| 2023 | 221 |
| 2022 | 392 |
| 2021 | 294 |
| 2020 | 273 |